Yohei Sekino
Overview
Explore the profile of Yohei Sekino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
551
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takemoto K, Kobatake K, Hatayama T, Tasaka S, Okazaki M, Nakano Y, et al.
Cancer Med
. 2025 Feb;
14(5):e70710.
PMID: 40013327
Introduction: Chronic kidney disease (CKD) is a risk factor for bladder cancer (BC) and is reportedly involved in its recurrence and progression. This study aimed to determine the molecular mechanisms...
2.
Hatayama T, Goto K, Kohada Y, Nishida K, Ueno T, Furutani T, et al.
World J Urol
. 2025 Feb;
43(1):132.
PMID: 39976660
Purpose: We aimed to evaluate the ability of the advanced lung cancer inflammation index (ALI) to predict the prognosis of patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial...
3.
Sekino Y, Nakahara H, Ikeda K, Kobatake K, Kohada Y, Tasaka R, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941725
: It is said that genes that escape from X chromosome inactivation (XCI) contribute to gender differences. We analyzed the prognostic role of these genes and identified a gender-biased difference...
4.
Kobatake K, Goto K, Sakamoto Y, Iwane K, Nishida K, Hashimoto K, et al.
Int J Urol
. 2025 Feb;
PMID: 39930593
Objective: This study evaluated whether first-line treatment affects survival outcomes in patients with advanced urothelial carcinoma undergoing sequential therapy with chemotherapy, immune checkpoint inhibitors, and enfortumab vedotin. Methods: This multicenter...
5.
Tohi Y, Kobayashi K, Daizumoto K, Sekino Y, Fukuhara H, Niigawa H, et al.
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39893578
Objective: To evaluate the real-world clinical usage and effectiveness of apalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods: We retrospectively reviewed the data of 186 men who received...
6.
Kobayashi G, Sekino Y, Nakahara H, Kobatake K, Goto K, Hayashi T, et al.
J Cancer Res Clin Oncol
. 2024 Dec;
151(1):18.
PMID: 39739128
Background: Urothelial carcinoma (UC) is a common type of malignant disease; however, the diagnostic and prognostic markers of upper urinary tract urothelial cancer (UTUC) remain poorly understood because of its...
7.
Hinata N, Fujisawa M, Yamaguchi R, Katsura D, Kitano H, Sekino Y, et al.
Int J Urol
. 2024 Dec;
PMID: 39670346
Objectives: To evaluate the safety, efficacy, and patient-reported outcomes of Aquablation therapy using the AQUABEAM Robotic System for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic...
8.
Kobatake K, Goto K, Honda Y, Naito M, Takemoto K, Miyamoto S, et al.
World J Urol
. 2024 Oct;
42(1):571.
PMID: 39382717
Purpose: Positive surgical margins (PSM) after robot-assisted radical prostatectomy (RARP) for prostate cancer (PCa) can increase the risk of biochemical recurrence and PCa-specific mortality. We aimed to evaluate the impact...
9.
Nakano Y, Sekino Y, Takemoto K, Ueno T, Fujii S, Kitano H, et al.
IJU Case Rep
. 2024 Sep;
7(5):371-374.
PMID: 39224685
Introduction: Fungal balls in the urinary tract are rare but dangerous complications of candiduria. Here, we report a case of a urinary tract fungal ball in a single kidney after...
10.
Kohada Y, Kitano H, Tasaka R, Miyamoto S, Hatayama T, Shikuma H, et al.
Int J Urol
. 2024 Jul;
31(10):1145-1152.
PMID: 39016443
Objectives: This study aimed to elucidate the clinical characteristics and predictors of long-term postoperative urinary incontinence (PUI) after robot-assisted radical prostatectomy (RARP). Methods: This study included patients who underwent RARP...